Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013

Drake, Marcus; Apostolidis, Apostolos; Cocci, Andrea; Emmanuel, Anton; Gajewski, Jerzy; Harrison, Simon; Heesakkers, John; Lemack, Gary E.; Madersbacher, H.; Panicker, Jalesh N.; Radziszewski, Piotr; Sakakibara, Ryuji; Wyndaele, Jean Jacques

doi:10.1002/nau.23027

Cited by 96 publications

(87 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, the management of SUI has always been more challenging than the management of urge incontinence [1]. Various treatment options exist, such as artificial sphincters and hydraulic prostheses, which are considered effective but expose patients to an elevated risk of erosion [2]. Mtany injectable agents have already been described.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Stress Urinary Incontinence in Neurological Patients With an Injectable Elastomer Prosthesis: Preliminary Results

et al. 2017

View full text Add to dashboard Cite

Many treatment options for stress urinary incontinence are difficult to apply to neurological patients. Urolastic is a new agent that is primarily indicated for women with mild stress urinary incontinence or men after prostate surgery. In this report, we present a series of 5 cases describing the first use of Urolastic to treat neurological patients. All patients were evaluated with a voiding diary and the use of auxiliary devices as the main indicators of continence. The median operative time was 30.8 minutes, and no complications were observed. Of the 5 patients, 4 reported improved incontinence: 2 switched from diapers to small pads, while the other 2 patients were able to discontinue urinary condom use. The only instance of treatment failure occurred in a patient with a low-compliance bladder. The advantages of this procedure appear to include a soft-cuff effect, reversibility, and minimal invasiveness. However, a future randomized study would be necessary to validate this treatment option.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of Stress Urinary Incontinence in Neurological Patients With an Injectable Elastomer Prosthesis: Preliminary Results

et al. 2017

View full text Add to dashboard Cite

show abstract

“…SNS aims to restore bladder neural control for both OAB and urinary retention 8,31,32. The technique was developed by Tanagho and Schmidt in the late eighties for neurogenic bladder disease.…”

Section: Neuromodulationmentioning

confidence: 99%

“…These muscarinic receptors are the main pharmacological target sites to treat OAB (Figure 2). Examples of this are widespread use of antimuscarinics and intradetrusor botulinum toxin A injections that are both evidence-based therapies that are included in all major therapy guidelines for neurogenic OAB and iOAB 8–10…”

Section: Introductionmentioning

confidence: 99%

Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives

Janssen¹,

Martens²,

Wall³

et al. 2017

MDER

View full text Add to dashboard Cite

ObjectivesThis review describes the evidence from established and experimental therapies that use electrical nerve stimulation to treat lower urinary tract dysfunction.MethodsClinical studies on established treatments such as percutaneous posterior tibial nerve stimulation (P-PTNS), transcutaneous electrical nerve stimulation (TENS), sacral nerve stimulation (SNS) and sacral anterior root stimulation (SARS) are evaluated. In addition, clinical evidence from experimental therapies such as dorsal genital nerve (DGN) stimulation, pudendal nerve stimulation, magnetic nerve stimulation and ankle implants for tibial nerve stimulation are evaluated.ResultsSNS and P-PTNS have been investigated with high-quality studies that have shown proven efficacy for the treatment for overactive bladder (OAB). SARS has proven evidence-based efficacy in spinal cord patients and increases the quality of life. TENS seems inferior to other OAB treatments such as SNS and P-PTNS but is noninvasive and applicable for ambulant therapy. Results from studies on experimental therapies such as pudendal nerve stimulation seem promising but need larger study cohorts to prove efficacy.ConclusionNeurostimulation therapies have proven efficacy for bladder dysfunction in patients who are refractory to other therapies.SignificanceRefinement of neurostimulation therapies is possible. The aim should be to make the treatments less invasive, more durable and more effective for the treatment of lower urinary tract dysfunction.

show abstract

“…1 NDO leads to a negative impact on a patient's quality of life (QOL) 2 and may contribute to deterioration of the upper urinary tract. 3 Accordingly, urodynamic study (UDS) findings including impaired detrusor compliance with a high detrusor leak point pressure, detrusor sphincter dyssynergia (DSD), and vesicoureteral reflux (VUR) require special attention in neurogenic bladder patients. 3 …”

Section: Introductionmentioning

confidence: 99%

“…3 Accordingly, urodynamic study (UDS) findings including impaired detrusor compliance with a high detrusor leak point pressure, detrusor sphincter dyssynergia (DSD), and vesicoureteral reflux (VUR) require special attention in neurogenic bladder patients. 3 …”

Section: Introductionmentioning

confidence: 99%

Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

Kaviani

Khavari

2017

Urologic Clinics of North America

View full text Add to dashboard Cite

Intradetrusor injection of botulinum toxin A (BTX-A) is an effective option in the management of patients with neurogenic detrusor overactivity (NDO) who do not respond to or tolerate oral pharmacologic agents. There is level I evidence that intradetrusor injection of onabotulinumtoxinA for the treatment of refractory NDO in patients with multiple sclerosis and spinal cord injury is associated with a significantly greater achievement of patients' goals and improved performance in urodynamic studies than results with placebo. Only pilot studies or small case series support the use of BTX-A for NDO in patients with Parkinson's disease (PD) and cerebrovascular accident (CVA). BTX-A seems to be effective in children with myelomeningocele (MMC) but this statement is not supported by high level of evidence.

show abstract

Neurogenic lower urinary tract dysfunction: Clinical management recommendations of the Neurologic Incontinence committee of the fifth International Consultation on Incontinence 2013

Cited by 96 publications

References 11 publications

Treatment of Stress Urinary Incontinence in Neurological Patients With an Injectable Elastomer Prosthesis: Preliminary Results

Treatment of Stress Urinary Incontinence in Neurological Patients With an Injectable Elastomer Prosthesis: Preliminary Results

Clinical utility of neurostimulation devices in the treatment of overactive bladder: current perspectives

Disease-Specific Outcomes of Botulinum Toxin Injections for Neurogenic Detrusor Overactivity

Contact Info

Product

Resources

About